Diametric Capital, LP Akebia Therapeutics, Inc. Transaction History
Diametric Capital, LP
- $118 Million
- Q4 2024
A detailed history of Diametric Capital, LP transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Diametric Capital, LP holds 88,115 shares of AKBA stock, worth $187,684. This represents 0.14% of its overall portfolio holdings.
Number of Shares
88,115Holding current value
$187,684% of portfolio
0.14%Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
131Shares Held
61.9MCall Options Held
171KPut Options Held
185K-
Black Rock Inc. New York, NY11.6MShares$24.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$23.2 Million0.0% of portfolio
-
State Street Corp Boston, MA6.3MShares$13.4 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$12.2 Million20.26% of portfolio
-
Geode Capital Management, LLC Boston, MA4.8MShares$10.2 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $392M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...